2021 American Society of Hematology Annual Meeting*

Results from the pivotal phase II trial of mosunetuzumab showed significantly higher CR rates vs historical control in patients with relapsed/refractory FL and ≥2 previous lines of therapy.

Tisagenlecleucel demonstrated high response rate and durability in patients with high-risk R/R FL, including POD24 and high TMTV though reduced in comparison to low-risk disease.

ZUMA-7 met the primary endpoint demonstrating a >4-fold improvement in EFS with axicabtagene ciloleucel vs standard of care.

Valemetostat yielded an ORR of 48% in patients with R/R ATL, most of whom had received prior treatment with mogamulizumab.

Event-based analyses show that acalabrutinib had a lower incidence, exposure-adjusted incidence, and exposure-adjusted time with events of CV-related toxicities (eg, afib/flutter, hypertension, and bleeding) compared with ibrutinib in this head-to-head phase III trial.

Parsaclisib, a first-in-class selective PI3Kδ inhibitor, demonstrated promising efficacy and safety in patients with BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.

MK-1026 was active and tolerable in this phase II study, which enrolled patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those who progressed on a previous BTK inhibitor.

In patients with relapsed/refractory CLL, prolonged PFS with acalabrutinib vs idelalisib/rituximab or bendamustine/rituximab was maintained after a median follow-up of 3 years.

In patients with previously untreated CLL/SLL, zanubrutinib resulted in superior progression-free survival vs bendamustine plus rituximab.

Results of this study showed that substantial proportions of clinical relapses were radiographically detected in asymptomatic patients, whereas immunosequencing MRD monitoring demonstrated suboptimal sensitivity.

The addition of venetoclax to DA-EPOCH-R in patients with previously untreated double-hit lymphoma was associated with excess treatment-related toxicity and mortality.

Initial therapy with ibrutinib + venetoclax for 12 cycles resulted in a 2-year DFS rate of 95.3% in patients with undetectable MRD who were subsequently randomized to placebo and 100% in those subsequently randomized to ibrutinib.

Updated results from the phase III GLOW trial show that first-line, fixed-duration ibrutinib + venetoclax confers deep and prolonged undetectable MRD responses, leading to favorable PFS outcomes for older or unfit patients with CLL.

Results from this trial showed that parsaclisib conferred rapid and durable responses in most patients with R/R FL, with a manageable safety profile.

Significant and clinically meaningful improvement in EFS was observed with liso-cel vs SoC as second-line therapy in patients with LBCL refractory to or relapsed ≤12 months after first-line therapy.

In the phase III POLARIX trial, polatuzumab vedotin plus R-CHP significantly increased progression-free survival vs R-CHOP in patients with previously untreated intermediate- or high-risk DLBCL.

In the phase III BELINDA trial, tisagenlecleucel as second-line therapy in patients with R/R aggressive B-cell NHL had no significant impact on event-free survival vs standard of care.